Back to search
Ribavirin Compared With Standard Care in Treating Patients With Respiratory Syncytial Virus Following Stem Cell Transplantation
NCT00016081
PHASE3INTERVENTIONAL
Fred Hutchinson Cancer Center
NULL participants
Started 1998-03 · Completed 2003-03
Status: Completed (as of 12-23-2025)
Conditions
Infection
Interventions
Linked Papers (from SciSciNet-V2)
Total Papers0
Background
0Result
0Derived
0Unknown
0Brief Summary
RATIONALE: Antivirals such as ribavirin are used to treat infections caused by viruses. It is not yet known if ribavirin is more effective than standard therapy in preventing pneumonia in patients who have respiratory syncytial virus (RSV) infection following stem cell transplantation. PURPOSE: Randomized phase III trial to compare the effectiveness of ribavirin with that of standard therapy in preventing pneumonia in patients who have RSV infection following stem cell transplantation.
No papers linked to this trial in SciSciNet
Visit ClinicalTrials.gov for more information about this study